The Company’s Product, hyaluronic acid Flexotron Forte (1%) has obtained medical device license.

 The Company's Product, hyaluronic acid
Flexotron Forte (1%) has obtained medical device
license.

1.Date of occurrence of the event:2022/06/09
2.Company name:SciVision Biotech Inc.
3.Relationship to the Company (please enter "head office" or
  "subsidiaries"):Head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:Flexotron Forte(1%), hyaluronic acid developed and
produced by the company, has passed and obtained the medical device
license (P3H 2022/17365).
6.Countermeasures:make this announcement
7.Any other matters that need to be specified:This product contains
hyaluronic acid, which can increase joint lubrication and reduce joint
friction. For the majority of patients with degenerative knee arthritis,
it can inhibit the degeneration of cartilage, promote its metabolism,
relieve pain and discomfort, improve daily activities and increase range
of activities of joints. Russia has a population of 147 million, of which
about 13% have osteoarthritis. The company has obtained the Russian
national medical device license, which can increase the sales performance
in the Russian market and contribute to the company's revenue.